Evidence map›Paper›PMID 34255700›Full record

ArticleJMIR medical informatics2021

Frequency of Participation in External Quality Assessment Programs Focused on Rare Diseases: Belgian Guidelines for Human Genetics Centers.

Joséphine Lantoine, Anne Brysse, Vinciane Dideberg, Kathleen Claes, Sofie Symoens, Wim Coucke, Valérie Benoit, Sonia Rombout, Martine De Rycke, Sara Seneca and 10 more

Abstract read
In one paragraph

Article in JMIR medical informatics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Joséphine LantoineRare Diseases Unit, Department of Quality of Laboratories, Sciensano, Brussels, Belgium.ORCID https://orcid.org/0000-0001-7205-3601
Anne BrysseCenter of Human Genetics, CHU of Liège, University of Liège, Liège, Belgium.ORCID https://orcid.org/0000-0002-0970-3197
Vinciane DidebergCenter of Human Genetics, CHU of Liège, University of Liège, Liège, Belgium.ORCID https://orcid.org/0000-0002-9998-6687
Kathleen ClaesCenter for Medical Genetics, Ghent University Hospital, Gent, Belgium.ORCID https://orcid.org/0000-0003-0841-7372
Sofie SymoensCenter for Medical Genetics, Ghent University Hospital, Gent, Belgium.ORCID https://orcid.org/0000-0003-4240-2772
Wim CouckeDepartment of Quality of Laboratories, Sciensano, Brussels, Belgium.ORCID https://orcid.org/0000-0002-4290-4628
Valérie BenoitCenter of Human Genetics, Institut de Pathologie et de Génétique, Gosselies, Belgium.ORCID https://orcid.org/0000-0002-1098-9452
Sonia RomboutCenter of Human Genetics, Institut de Pathologie et de Génétique, Gosselies, Belgium.ORCID https://orcid.org/0000-0003-2479-3204
Martine De RyckeCenter for Medical Genetics, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.ORCID https://orcid.org/0000-0001-7861-9426
Sara SenecaCenter for Medical Genetics, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium.ORCID https://orcid.org/0000-0002-0853-9890
Lut Van LaerCenter of Medical Genetics, Antwerp University Hospital and University of Antwerp, Edegem, Belgium.ORCID https://orcid.org/0000-0003-1394-9867
Wim WuytsCenter of Medical Genetics, Antwerp University Hospital and University of Antwerp, Edegem, Belgium.ORCID https://orcid.org/0000-0002-4349-9038
Anniek CorveleynCenter for Human Genetics, University Hospitals Leuven, Leuven, Belgium.ORCID https://orcid.org/0000-0001-6253-8568
Kris Van Den BogaertCenter for Human Genetics, University Hospitals Leuven, Leuven, Belgium.ORCID https://orcid.org/0000-0003-4525-5907
Catherine RydlewskiCenter of Human Genetics, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.ORCID https://orcid.org/0000-0002-7155-2596
Françoise WilkinCenter of Human Genetics, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.ORCID https://orcid.org/0000-0001-6589-3100
Marie RavoetCenter for Human Genetics, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium.ORCID https://orcid.org/0000-0002-0900-9947
Elodie FastréCenter for Human Genetics, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium.ORCID https://orcid.org/0000-0002-6583-4933
Arnaud CapronDepartment of Quality of Laboratories, Sciensano, Brussels, Belgium.ORCID https://orcid.org/0000-0002-4477-7909
Nathalie Monique VandeveldeRare Diseases Unit, Department of Quality of Laboratories, Sciensano, Brussels, Belgium.ORCID https://orcid.org/0000-0003-0157-7963

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundParticipation in quality controls, also called external quality assessment (EQA) schemes, is required for the ISO15189 accreditation of the Medical Centers of Human Genetics. However, directives on the minimal frequency of participation in genetic quality control schemes are lacking or too heterogeneous, with a possible impact on health care quality.

objectiveThe aim of this project is to develop Belgian guidelines on the frequency of participation in quality controls for genetic testing in the context of rare diseases.

methodsA group of experts analyzed 90 EQA schemes offered by accredited providers and focused on analyses used for the diagnosis of rare diseases. On that basis, the experts developed practical recommendations about the minimal frequencies of participation of the Medical Centers of Human Genetics in quality controls and how to deal with poor performances and change management. These guidelines were submitted to the Belgian Accreditation Body and then reviewed and approved by the Belgian College of Human Genetics and Rare Diseases and by the National Institute for Health and Disability Insurance.

resultsThe guidelines offer a decisional algorithm for the minimal frequency of participation in human genetics EQA schemes. This algorithm has been developed taking into account the scopes of the EQA schemes, the levels of experience, and the annual volumes of the Centers of Human Genetics in the performance of the tests considered. They include three key principles: (1) the recommended annual assessment of all genetic techniques and technological platforms, if possible through EQAs covering the technique, genotyping, and clinical interpretation; (2) the triennial assessment of the genotyping and interpretation of specific germline mutations and pharmacogenomics analyses; and (3) the documentation of actions undertaken in the case of poor performances and the participation to quality control the following year. The use of a Bayesian statistical model has been proposed to help the Centers of Human Genetics to determine the theoretical number of tests that should be annually performed to achieve a certain threshold of performance (eg, a maximal error rate of 1%). Besides, the guidelines insist on the role and responsibility of the national public health authorities in the follow-up of the quality of analyses performed by the Medical Centers of Human Genetics and in demonstrating the cost-effectiveness and rationalization of participation frequency in these quality controls.

conclusionsThese guidelines have been developed based on the analysis of a large panel of EQA schemes and data collected from the Belgian Medical Centers of Human Genetics. They are applicable to other countries and will facilitate and improve the quality management and financing systems of the Medical Centers of Human Genetics.

Indexed as

algorithmcost-effectivenessexternal quality assessmentfrequencygeneticsgenetic testinghealth informaticshuman geneticsmedical informaticsproficiency testingpublic healthquality controlrare diseasessurveillance, public health authorities

Identifiers

PMID34255700
PMCPMC8314149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.